Genetic mutations and immune microenvironment: unveiling the connection to AML prognosis

References

• Dozzo A, Galvin A, Shin JW, et al. Modelling acute myeloid leukemia (AML): what's new? a transition from the classical to the modern. Drug Deliv Transl Res. 2023;13(8):2110–2141. doi:10.1007/s13346-022-01189-4
   PubMed Web of Science ®Google Scholar
• Kaplan ZL, Van Leeuwen N, Posthuma EF. Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in The Netherlands: a long haul is needed to change nothing into something. Leukemia. 2022;36(2), doi:10.1038/S41375-021-01503-Y
   Web of Science ®Google Scholar
• Pozanski SM, Ashkar AA. What defines NK cell functional fate: phenotype or Metabolism? Front Immunol. 2019;10:1414, doi:10.3389/fimmu.2019.01414
   PubMed Web of Science ®Google Scholar
• Terren I, Orrantia A, Vitalle J, et al. NK cell metabolism and tumor microenvironment. Front Immunol. 2019;10:2278, doi:10.3389/fimmu.2019.02278
   PubMed Web of Science ®Google Scholar
• Prabhala R, Pierceall WE, Samur M, et al. Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival. Front Oncol. 2023;13:1271807, doi:10.3389/fonc.2023.1271807
   PubMed Web of Science ®Google Scholar
• Heuser-Loy C, Baumgart AK, Hackstein CP, et al. Conditional NKT cell depletion. in mice reveals a negative feedback loop that regulates CTL cross-priming. J Immunol. 2024;212(1):35–42. doi:10.4049/jimmunol.2300662
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Cianga VA, Campos Catafal L, Cianga P, et al. Natural killer cell subpopulations and inhibitory receptor dynamics in myelodysplastic syndromes and acute myeloid leukemia. Front Immunol. 2021;12:665541, doi:10.3389/fimmu.2021.665541
   PubMed Web of Science ®Google Scholar
• Cao G, Yue J, Yetian R, et al. Single-cell dissection of cervical cancer reveals key subsets of the tumor immune microenvironment. EMBO J. 2023: e110757, doi:10.15252/embj.2022110757
   PubMed Web of Science ®Google Scholar
• Amankulov J, Kaidarova D, Zholdybay Z, et al. Natural killer cell activity level in colorectal cancer screening in an average risk population. Arch Med Sci. 2021;19(6):1747–1752. doi:10.5114/aoms/142101
   PubMed Web of Science ®Google Scholar
• Shin E, Bak SH, Park T, et al. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond. Front Immunol. 2023;14:1192907, doi:10.3389/fimmu.2023.1192907
   PubMedGoogle Scholar
• Park SH, Bae MH, Park CJ, et al. Effect of changes in lymphocyte subsets at diagnosis in acute myeloid leukemia on prognosis: association with complete remission rates and relapse free survivals. J Hematop. 2023;16(2):73–84. doi:10.1007/s12308-023-00536-9
   PubMed Web of Science ®Google Scholar
• Dogra P, Rancan C, Ma W, et al. Tissue Determinants of Human NK Cell Development, Function, and Residence. Cell. 2020;180(4):749–763.e13. doi:10.1016/j.cell.2020.01.022
   PubMed Web of Science ®Google Scholar
• Behnaz V, Ali A, Naderali E, et al. Cord blood stem cell derived CD16 + NK cells eradicated acute lymphoblastic leukemia cells using with anti-CD47 antibody. Life Sci. 2020;242(C). doi:10.1016/j.lfs.2019.117223
   Google Scholar
• Kim S, Choi J. Restoring NK cell functions in AML relapse. Blood. 2022;140(26):2765–2766. doi:10.1182/blood.2022018079
   PubMed Web of Science ®Google Scholar
• Bayatipoo H, Mehdizadeh S, Jafarpour R, et al. Role of NKT cells in cancer immunotherapy—from bench to bed. Med Oncol. 2022;40(1). doi:10.1007/S12032-022-01888-5
   Web of Science ®Google Scholar
• Li MO, Wolf N, Raulet DH, et al. Innate immune cells in the tumor microenvironment. Cancer Cell. 2021;39(6), doi:10.1016/J.CCELL.2021.05.016
   Web of Science ®Google Scholar
• Tiwary S, Berzofsky JA, Terabe M. Altered lipid tumor environment and its potential effects on NKT cell function in tumor immunity. Front Immunol. 2019;10:2187, doi:10.3389/fimmu.2019.02187
   PubMed Web of Science ®Google Scholar
• Zhou L, Adrianto I, Wang J, et al. Single-Cell RNA-Seq analysis uncovers distinct functional human NKT cell Sub-populations in peripheral blood. Front Cell Dev Bio. 2020: 8, doi:10.3389/fcell.2020.00384
   PubMed Web of Science ®Google Scholar
• Arellano-Ballestero H, Sabry M, Lowdell MW. A Killer Disarmed: natural Killer Cell Impairment in Myelodysplastic Syndrome. Cells. 2023;12(4):633, doi:10.3390/cells12040633
   PubMed Web of Science ®Google Scholar
• Stringaris K, Sekine T, Khoder A, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failuretoachieve remission in acute myeloid leukemia. Haematologica. 2014;99(5):836–847. doi:10.3324/haematol.2013.087536
   PubMed Web of Science ®Google Scholar
• Szczepanski MJ, Szajnik M, Welsh A, et al. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immun. 2010;59:73–79. doi:10.1007/s00262-009-0724-5
   PubMed Web of Science ®Google Scholar
• Costello RT, Sivori S, Marcenaro E, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood. 2002;99(10):3661–3667. doi:10.1182/blood.V99.10.3661
   PubMed Web of Science ®Google Scholar
• Hamidreza Z, Maryam B, Abdullatif A, et al. Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights. Cell Commun Signal. 2022;20(1), doi:10.1186/S12964-022-00956-7
   Web of Science ®Google Scholar
• Niparuck P, Limsuwanachot N, Pukiat S, et al. Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia. Exp Hematol Oncol. 2019;8:3, doi:10.1186/s40164-019-0127-z
   PubMed Web of Science ®Google Scholar
• Liu SB, Dong HJ, Bao XB, et al. ImPact of FLT3-ITD length on Prognosis of acute myeloid leukemia. Haematologica. 2019;104(1):e9–e12. doi:10.3324/haematol.2018.191809
   PubMed Web of Science ®Google Scholar
• Alexandra J, Ulrike B, Mueller BU, et al. Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression. Hematol Oncol. 2018;36(3), doi:10.1002/hon.2516
   Web of Science ®Google Scholar